This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (65)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Associations With Medication and Medical Utilization and Spending and Health

Dana P. Goldman, PhD; Geoffrey F. Joyce, PhD; Yuhui Zheng, MPhil

JAMA. 2007;298:61-69.

Context  Prescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug cost sharing could affect access to them.

Objective  To synthesize published evidence on the associations among cost-sharing features of prescription drug benefits and use of prescription drugs, use of nonpharmaceutical services, and health outcomes.

Data Sources  We searched PubMed for studies published in English between 1985 and 2006.

Study Selection and Data Extraction  Among 923 articles found in the search, we identified 132 articles examining the associations between prescription drug plan cost-containment measures, including co-payments, tiering, or coinsurance (n = 65), pharmacy benefit caps or monthly prescription limits (n = 11), formulary restrictions (n = 41), and reference pricing (n = 16), and salient outcomes, including pharmacy utilization and spending, medical care utilization and spending, and health outcomes.

Results  Increased cost sharing is associated with lower rates of drug treatment, worse adherence among existing users, and more frequent discontinuation of therapy. For each 10% increase in cost sharing, prescription drug spending decreases by 2% to 6%, depending on class of drug and condition of the patient. The reduction in use associated with a benefit cap, which limits either the coverage amount or the number of covered prescriptions, is consistent with other cost-sharing features. For some chronic conditions, higher cost sharing is associated with increased use of medical services, at least for patients with congestive heart failure, lipid disorders, diabetes, and schizophrenia. While low-income groups may be more sensitive to increased cost sharing, there is little evidence to support this contention.

Conclusions  Pharmacy benefit design represents an important public health tool for improving patient treatment and adherence. While increased cost sharing is highly correlated with reductions in pharmacy use, the long-term consequences of benefit changes on health are still uncertain.

Author Affiliations: Health Economics, Finance, and Organization (Drs Goldman and Joyce) and Pardee RAND Graduate School (Ms Zheng), RAND, Santa Monica, California.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage?
Wetmore et al.
Nephrol Dial Transplant 2009;0:gfp396v1-gfp396.
ABSTRACT | FULL TEXT  

Developing A Policy For Second-Generation Antipsychotic Drugs
Rosenheck and Sernyak
Health Aff (Millwood) 2009;28:w782-w793.
ABSTRACT | FULL TEXT  

Single Payer--Good Metaphor, Bad Politics
Stone
Journal of Health Politics, Policy and Law 2009;34:531-542.
ABSTRACT  

Formulary Coverage for Lipid-Lowering Drugs Recommended for Children
Yoon et al.
CLIN PEDIATR 2009;48:609-613.
ABSTRACT  

Medicaid Prescription Drug Policies and Medication Access and Continuity: Findings From Ten States
West et al.
Psychiatr. Serv. 2009;60:601-610.
ABSTRACT | FULL TEXT  

Drug Company-Sponsored Patient Assistance Programs: A Viable Safety Net?
Choudhry et al.
Health Aff (Millwood) 2009;28:827-834.
ABSTRACT | FULL TEXT  

The Year in Epidemiology, Health Services Research, and Outcomes Research
Hlatky and Heidenreich
J Am Coll Cardiol 2009;53:1459-1466.
FULL TEXT  

Cost-Related Medication Underuse: A Window Into Patients' Medication-Related Concerns
Piette
Diabetes Spectr. 2009;22:77-80.
ABSTRACT | FULL TEXT  

Impact of Obtaining Medications from Pharmaceutical Company Assistance Programs on Therapeutic Goals
Trompeter and Havrda
The Annals of Pharmacotherapy 2009;43:469-477.
ABSTRACT | FULL TEXT  

Copayment Levels and Medication Adherence: Less Is More
Choudhry
Circulation 2009;119:365-367.
FULL TEXT  

Impact of a Prescription Copayment Increase on Lipid-Lowering Medication Adherence in Veterans
Doshi et al.
Circulation 2009;119:390-397.
ABSTRACT | FULL TEXT  

Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point
Aitken et al.
Health Aff (Millwood) 2009;28:w151-w160.
ABSTRACT | FULL TEXT  

Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: A Systematic Review and Meta-analysis
Kesselheim et al.
JAMA 2008;300:2514-2526.
ABSTRACT | FULL TEXT  

Protect the sick: health insurance reform in one easy lesson.
Stone
J Law Med Ethics 2008;36:652-659.
 

Medicaid Prescription Formulary Restrictions and Arthritis Treatment Costs
Johnson and Stahl-Moncada
AJPH 2008;98:1300-1305.
ABSTRACT | FULL TEXT  

Beyond The Efficiency Index: Finding A Better Way To Reduce Overuse And Increase Efficiency In Physician Care
Greene et al.
Health Aff (Millwood) 2008;27:w250-w259.
ABSTRACT | FULL TEXT  

Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making
Rosenheck et al.
Psychiatr. Serv. 2008;59:515-520.
ABSTRACT | FULL TEXT  

Model for medication therapy management in a university clinic
Kliethermes et al.
Am J Health Syst Pharm 2008;65:844-856.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post-Myocardial Infarction Medicare Beneficiaries
Choudhry et al.
Circulation 2008;117:1261-1268.
ABSTRACT | FULL TEXT  

France's health care system
Dhalla and Thomson
CMAJ 2008;178:596-596.
FULL TEXT  

Impact Of Decreasing Copayments On Medication Adherence Within A Disease Management Environment
Chernew et al.
Health Aff (Millwood) 2008;27:103-112.
ABSTRACT | FULL TEXT